Scientific article demonstrates that PExA can enable rapid diagnosis of the disease state PGD
This is a Google translated news text!
An international research group describes in a recently published scientific article how PExA can enable non-invasive and rapid diagnostics as well as increased understanding of primary graft dysfunction (PGD), which is a common complication for lung transplant recipients.
A scientific article in which PExA was used to study lung transplanted individuals has recently been published in Transplant International [1] . The article describes how researchers from Lund, led by Professor Sandra Lindstedt, studied the disease state PGD, which is the most common early cause of death in lung transplantation.
PGD or primary graft dysfunction is a reaction that can lead to organ rejection and occurs in the first few days after lung transplantation. The condition is currently detected by measuring blood gases and X-rays, but according to the researchers, improved methods are needed to be able to monitor the patient directly at the hospital bed and to be able to study the mechanisms that drive PGD
In the study, a PExA instrument has been connected directly to a mechanical ventilator to continuously record and collect particles from transplanted individuals.
Among the results, a connection between variation in the particle flow and the occurrence of PGD is demonstrated, which means that the method may be implemented as an important diagnostic tool for the early detection of PGD. Furthermore, it is described that biomaterial can be collected easily and non-invasively from the small airways without having to do biopsy or lung lavage as before. This opens up new opportunities to understand the disease state in more detail.
Professor Sandra Lindstedt at Lund University comments:
- We have built up solid experience with PExA in our lung research and can now begin to see patterns for disease directly through particle flow measurements and indirectly through the protein profiling we do on the collected material. This creates new conditions for an increased understanding and early detection of lung diseases, which can be of great importance for the efficiency of healthcare, but of course also for all patients with lung diseases.
The research has been conducted by researchers associated with Lund University, Skåne University Hospital and BioMS. The project has been financed by Knut and Alice Wallenberg Foundation, Marianne and Marcus Wallenberg Foundation, Vinnova, Center for Advanced Medical Products (CAMP), ALF-foundation, BioMS – the Swedish National Infrastructure for Biological Mass Spectrometry.
Tomas Gustafsson, CEO at PExA comments:
- It feels very exciting that reputable researchers such as Professor Lindstedts and her colleagues are now beginning to describe PExA as a future diagnostic instrument for lung diseases, which is completely in line with our long-term vision. We are now looking forward to more exciting results from the research that is being conducted in several lung diseases at Skåne University Hospital.
The article can be downloaded at: https://www.frontierspartnerships.org/articles/10.3389/ti.2024.12298/full
For further information, please contact:
Tomas Gustafsson, E-mail: info@pexa.se
Om PExA AB:
PExA AB (556956-9246) has developed PExA 2.1, a patented research instrument that helps researchers to intelligently collect biological samples from the smallest airways through a simple exhalation maneuver. PExA’s technology is currently used by prominent research groups in several different countries and research with the instrument has resulted in approximately 40 scientific publications, which serve as reference material for PExA’s method. The company’s long-term goal is to market and sell diagnostic instruments for popular diseases (e.g. lung cancer and COPD) to be used globally for diagnosis or general screening at facilities where care is offered. The company intends at the time it is relevant to sell to clinics to have developed more patient-friendly, flexible and commercial products, which means that PExA addresses a significantly wider market, which today includes several million patients globally.
PExA’s B share is listed on the Spotlight Stock Market.
[1] Transplant International is the official journal of The European Society for Organ Transplantation